Trustmark National Bank Trust Department Sells 4,449 Shares of Amgen Inc. (NASDAQ:AMGN)

Trustmark National Bank Trust Department trimmed its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 14.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 25,944 shares of the medical research company's stock after selling 4,449 shares during the quarter. Trustmark National Bank Trust Department's holdings in Amgen were worth $8,359,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of AMGN. Capital Performance Advisors LLP bought a new position in Amgen during the 3rd quarter valued at about $25,000. Strategic Financial Concepts LLC purchased a new position in shares of Amgen in the second quarter worth approximately $26,000. Hershey Financial Advisers LLC purchased a new stake in Amgen during the second quarter valued at approximately $30,000. nVerses Capital LLC bought a new position in Amgen in the 2nd quarter worth $31,000. Finally, Bbjs Financial Advisors LLC bought a new position in shares of Amgen in the second quarter worth about $33,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on AMGN. Dbs Bank upgraded shares of Amgen to a "strong-buy" rating in a research note on Monday, September 16th. Wells Fargo & Company cut shares of Amgen from an "overweight" rating to an "equal weight" rating and lifted their price objective for the company from $320.00 to $335.00 in a research report on Wednesday, August 7th. William Blair reaffirmed an "outperform" rating on shares of Amgen in a research note on Tuesday, November 12th. Royal Bank of Canada reissued an "outperform" rating and set a $362.00 price objective on shares of Amgen in a report on Thursday, September 26th. Finally, Truist Financial cut Amgen from a "buy" rating to a "hold" rating and lifted their target price for the stock from $320.00 to $333.00 in a report on Monday, October 14th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, Amgen presently has a consensus rating of "Moderate Buy" and a consensus target price of $333.57.

Amgen Stock Performance

AMGN stock opened at $287.87 on Thursday. Amgen Inc. has a one year low of $260.52 and a one year high of $346.85. The firm has a market cap of $154.74 billion, a price-to-earnings ratio of 36.86, a PEG ratio of 2.53 and a beta of 0.60. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The firm has a 50-day simple moving average of $318.08 and a two-hundred day simple moving average of $318.22.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. During the same quarter in the previous year, the business posted $4.96 EPS. Amgen's revenue was up 23.2% on a year-over-year basis. On average, equities analysts forecast that Amgen Inc. will post 19.51 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 3.13%. The ex-dividend date is Monday, November 18th. Amgen's dividend payout ratio is currently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.